Nexstim Plc – first NBT® system for depression ordered in the US

Helsinki, Finland: 22 May 2018 - Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company developing and commercializing its world-leading navigated non-invasive brain stimulation technology for therapeutic and diagnostic applications, announces that it has agreed to deliver its first Navigated Brain Therapy (NBT®) system in the US to Island Psychiatry, a private practice that provides accessible, high quality comprehensive mental healthcare on Long Island, New York. The placement follows Nexstim's launch of the SmartFocusTM TMS technology at the Clinical TMS (transcranial magnetic stimulation) Society Annual Meeting in New York, which took place from 11-13 May.

Island Psychiatry uses a Unified Specialities Approach that brings a variety of disciplines together to provide appropriate assessment and treatment including TMS for major depressive disorder for each individual patient. TMS is used to stimulate and increase the activity of an area of the brain called the left dorsolateral prefrontal cortex (DLPFC), where metabolic activity is reduced in depression. Island Psychiatry will use the NBT® system to provide patients with personalised navigated TMS therapy.

More info on Nexstim's website.


Next > Sensolus launches next generation tracking devices in cooperation with Jorjin Technologies Inc and STMicroelectronics

Previous > iSTAR Medical’s MINIject delivers exceptional 6-month results